Stem Cell Therapy for Scleroderma: Can It Slow Skin and Organ Fibrosis?

Scleroderma is a disease that quietly reshapes the body from the inside out. Skin tightens and thickens, and in more severe cases, internal organs — lungs, heart, kidneys, digestive tract — can scar and lose function over time. For patients living with it, the frustrating reality is that current treatments largely manage symptoms without reliably stopping the underlying fibrotic process.

That gap has pushed research toward regenerative approaches, and stem cell therapy for scleroderma has become one of the more actively studied options in autoimmune connective tissue disease. This article walks through what scleroderma actually does to the body, what current treatments can and can’t achieve, and what real clinical trials and research studies say about stem cells — without overstating what the evidence currently supports.

Scleroderma, medically known as systemic sclerosis, is an autoimmune connective tissue disease. It develops through three overlapping processes working together:

• Immune dysregulation — The immune system becomes chronically activated, producing autoantibodies and inflammatory signaling that drive ongoing tissue damage.
• Collagen overproduction — Activated fibroblasts (the cells responsible for producing connective tissue) go into overdrive, laying down excess collagen. This is what causes the hallmark thickening and hardening of skin, and it can affect internal organs in the same way.
• Vascular damage — Blood vessels become damaged and narrowed, reducing blood flow to skin and organs, which both worsens tissue damage and contributes to complications like pulmonary hypertension.

Together, these three processes — immune dysfunction, fibrosis, and vasculopathy — explain why scleroderma is so difficult to treat with any single therapeutic approach.

Conventional scleroderma treatment typically includes immunosuppressive medications (such as mycophenolate mofetil or cyclophosphamide), and in some cases targeted antifibrotic drugs. These treatments can meaningfully slow disease progression for many patients, but they come with real limitations:

• They primarily dampen immune activity rather than reversing fibrosis that has already occurred.
• Long-term immunosuppression carries its own risks, including infection.
• Response varies considerably between patients, and some forms of scleroderma — particularly diffuse cutaneous disease with lung or heart involvement — progress despite standard therapy.
• None of the current standard drug options reliably reverse established skin or organ scarring.

This unmet need is exactly why researchers have turned to more intensive, cell-based approaches — including both hematopoietic stem cell transplantation (HSCT) and mesenchymal stem cell (MSC) therapy — as potential ways to interrupt the disease process itself rather than just suppress its symptoms.

It’s important to understand that “stem cell therapy” in scleroderma research actually refers to two quite different approaches, with different mechanisms and risk profiles.

Hematopoietic stem cell transplantation (HSCT) works by essentially resetting the immune system. A patient’s own blood-forming stem cells are collected, the existing immune system is depleted using chemotherapy (and sometimes radiation), and the stored stem cells are then reinfused to rebuild a new immune system. The stem cells themselves don’t directly repair fibrotic tissue — their role is to allow the toxic conditioning regimen to be given safely and to help rebuild immune function afterward.

Mesenchymal stem cell (MSC) therapy works through a different mechanism entirely. Rather than replacing the immune system, MSCs are thought to actively modulate it — through the following proposed actions:

• Immunomodulation — reducing inflammatory immune cell activity and supporting a more regulated immune response.
• Anti-fibrotic signaling — some preclinical research suggests MSCs may reduce the activity of fibroblasts and the profibrotic macrophages that drive collagen overproduction.
• Pro-angiogenic effects — supporting blood vessel repair, which may help address the vascular damage component of scleroderma.

This distinction matters for patients researching options: HSCT is a much more intensive, higher-risk procedure with the strongest clinical trial evidence behind it, while MSC therapy scleroderma research is a lower-risk, earlier-stage, and still-investigational area of study.

The strongest clinical trial evidence for any stem-cell-based approach in scleroderma comes from hematopoietic stem cell transplantation, tested in three major randomized controlled trials.

The ASTIS trial (Autologous Stem Cell Transplantation International Scleroderma), a phase 3 randomized trial across 10 countries, compared HSCT against monthly intravenous cyclophosphamide in 156 patients with early diffuse cutaneous systemic sclerosis. Long-term follow-up found improved event-free survival in the transplant group, though the trial also recorded a higher rate of early treatment-related mortality in the transplantation arm compared with the control group (van Laar et al., JAMA, 2014).

The SCOT trial (Scleroderma: Cyclophosphamide Or Transplantation) similarly randomized patients with severe scleroderma to myeloablative CD34+ selected autologous HSCT versus cyclophosphamide, and reported that transplantation led to better long-term outcomes on a composite score combining survival, lung function, disability, and skin thickness at 54 months, again confirming the general direction of the ASTIS findings (Sullivan et al., New England Journal of Medicine, 2018).

Alongside HSCT, a growing body of MSC-specific research has emerged. A systematic review and meta-analysis of MSC treatment in systemic sclerosis, covering 9 studies and 133 patients, found that modified Rodnan skin scores (a standard measure of skin fibrosis) significantly improved after MSC treatment compared to baseline (Stem Cell Research & Therapy, 2022). Separately, laboratory research has shown that MSCs pretreated with certain inflammatory signals reduced profibrotic macrophage accumulation and alleviated skin fibrosis in an animal model of scleroderma, offering a possible mechanistic explanation for these clinical observations (PMC, 2022).

A more recent comparative systematic review evaluating both HSCT and MSC-based transplantation concluded that HSCT has the strongest randomized trial evidence for long-term disease modification, while MSC therapy shows favorable, promising effects on skin fibrosis and lung involvement with a notably lower toxicity profile — though with less long-term survival data available so far (PMC, 2025).

In short: HSCT has the most robust clinical trial evidence for scleroderma, with meaningful benefit but real risk. MSC therapy shows encouraging early results with a much safer profile, but the evidence base is still developing.

Across the studies above, researchers have reported several potential benefits associated with stem-cell-based approaches, though outcomes vary by patient and by treatment type:

• Softening or stabilization of skin thickening (reduced modified Rodnan skin score)
• Improved or stabilized lung function in some patients
• Improved overall survival in HSCT trials specifically
• Reported improvements in quality-of-life measures in some studies

These findings are meaningful, but they come from specific trial populations under close medical supervision — they aren’t a guarantee of similar results for every patient.

HSCT is an intensive procedure and is not appropriate for every scleroderma patient. Clinical trials have generally restricted eligibility to patients with early diffuse cutaneous disease and significant risk of progression, while excluding those with more advanced organ damage (particularly advanced heart or lung involvement) due to increased procedural risk. Transplant-related mortality, while relatively low, was measurably higher than in the cyclophosphamide control groups in these trials.

MSC-based therapy generally carries a substantially lower risk profile, but it remains an investigational approach rather than an established, guideline-endorsed treatment for scleroderma. Candidacy for any regenerative approach should always be determined through a detailed medical evaluation, not a general online description.

If you’re exploring whether you might be a suitable candidate, our stem cell therapy for autoimmune diseases page provides more background, and reviewing stem cell therapy cost considerations can help you understand what’s involved before any consultation.

While specific protocols vary by clinic and by patient, a general regenerative evaluation for scleroderma typically involves:

• A detailed review of your diagnosis, disease subtype, organ involvement, and treatment history
• Diagnostic testing to assess current lung, heart, and skin status
• A discussion of whether mesenchymal stem cell treatment may be appropriate for your specific presentation, along with realistic expectations about outcomes
• Ongoing monitoring, since regenerative treatment does not replace the need for continued rheumatology follow-up

Some clinics also share patient success stories to give prospective patients a sense of others’ experiences — though, as with any individual account, these shouldn’t be read as a guarantee of similar results.

The evidence base for stem cell therapy for scleroderma is genuinely encouraging in places — particularly the randomized HSCT trial data — but it also comes with real trade-offs in risk, and the MSC-based research, while promising for scleroderma fibrosis treatment, is still an emerging field rather than an established cure. Early research suggests real potential; it doesn’t yet support guarantees.

If you’re living with scleroderma and want to understand whether any regenerative approach might fit your specific case, the most responsible next step is a personalized conversation with a specialist familiar with both the disease and the current evidence. You’re welcome to book a free consultation with our team to discuss your situation and questions.